0001453687-24-000027.txt : 20240104 0001453687-24-000027.hdr.sgml : 20240104 20240104170829 ACCESSION NUMBER: 0001453687-24-000027 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240102 FILED AS OF DATE: 20240104 DATE AS OF CHANGE: 20240104 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Davis Blaine CENTRAL INDEX KEY: 0001802188 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37798 FILM NUMBER: 24513145 MAIL ADDRESS: STREET 1: C/O ARTARA THERAPEUTICS, INC. STREET 2: 1 LITTLE WEST 12TH STREET CITY: NEW YORK STATE: NY ZIP: 10014 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Cartesian Therapeutics, Inc. CENTRAL INDEX KEY: 0001453687 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 65 GROVE STREET CITY: WATERTOWN STATE: MA ZIP: 02472 BUSINESS PHONE: 617-923-1400 MAIL ADDRESS: STREET 1: 65 GROVE STREET CITY: WATERTOWN STATE: MA ZIP: 02472 FORMER COMPANY: FORMER CONFORMED NAME: SELECTA BIOSCIENCES INC DATE OF NAME CHANGE: 20090109 4 1 wk-form4_1704406090.xml FORM 4 X0508 4 2024-01-02 0 0001453687 Cartesian Therapeutics, Inc. RNAC 0001802188 Davis Blaine C/O CARTESIAN THERAPEUTICS, INC. 704 QUINCE ORCHARD ROAD GAITHERSBURG MD 20878 0 1 0 0 Chief Financial Officer 0 Common Stock 2024-01-02 4 A 0 2424000 0 A 2424000 D Employee Stock Option (right to buy) 0.6552 2024-01-02 4 A 0 3110000 0 A 2034-01-01 Common Stock 3110000 3110000 D Each Restricted Stock Unit represents a contingent right to receive one share of common stock, which will vest as to 25% on January 2, 2025. The remainder of the underlying shares will vest in three equal annual installments thereafter so that the underlying shares will be fully vested on January 2, 2028. This option vests as to 25% on January 2, 2025. The remainder of the underlying shares will vest in three equal annual installments thereafter so that the underlying shares will be fully vested on January 2, 2028. Matthew Bartholomae, Attorney-in-Fact for Blaine Davis 2024-01-04